Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BeBetter MedSHSE:688759 -3.49%4 Net Current Asset Value is ¥3.39 as of Mar. 2026, which is 100% below its 10-year median of 9.52. GuruFocus rates SHSE:688759 with a GF Score™ of 4/100. Among 938 Biotechnology companies, BeBetter Med ranks worse than 63.01% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
BeBetter Med's net current asset value per share for the quarter that ended in Mar. 2026 was ¥3.39.
The historical rank and industry rank for BeBetter Med's Net Current Asset Value or its related term are showing as below:
SHSE:688759'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 6.6 Med: 9.52 Max: 10.81
Current: 6.6
During the past 7 years, the highest Price-to-Net-Current-Asset-Value Ratio of BeBetter Med was 10.81. The lowest was 6.60. And the median was 9.52.
SHSE:688759's Price-to-Net-Current-Asset-Value is ranked worse than 63.01% of 938
companies
in the Biotechnology industry
Industry Median: 4.72
vs SHSE:688759: 6.60
BeBetter Med (SHSE:688759) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
BeBetter Med Net Current Asset Value Related Terms
BeBetter Med Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for BeBetter Med's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688759 vs VRTX, REGN, RVMD: Net Current Asset Value Comparison
For the Biotechnology subindustry, BeBetter Med's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeBetter Med Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeBetter Med's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where BeBetter Med's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of ¥3.39 mean?
BeBetter Med (SHSE:688759) has a Net Current Asset Value of ¥3.39 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on BeBetter Med and its competitors. This is 64% below median its historical median of 9.52. Over the past decade, BeBetter Med's Net Current Asset Value has ranged from 6.60 to 10.81. According to the industry distribution chart, BeBetter Med ranks #591 out of 938 companies in the Biotechnology industry, placing it in the top 63%.
Is BeBetter Med's Net Current Asset Value too high?
BeBetter Med's current Net Current Asset Value of ¥3.39 is 64% below median its 10-year median of 9.52. Over the past 10 years, this metric has ranged from a low of 6.60 to a high of 10.81. Based on the distribution chart, BeBetter Med ranks #591 out of 938 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BeBetter Med has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BeBetter Med's Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BeBetter Med ranks #591 out of 938 companies for Net Current Asset Value. This places BeBetter Med in the lower half of its industry. The industry median Net Current Asset Value is 4.72. Historically, BeBetter Med's own Net Current Asset Value has ranged from 6.60 to 10.81 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.72, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on BeBetter Med and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeBetter Med's current Net Current Asset Value is ¥3.39, which is 64% below median its own 10-year median of 9.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeBetter Med stock overvalued right now?
BeBetter Med (SHSE:688759) has a current Net Current Asset Value of ¥3.39. The current Net Current Asset Value is ¥3.39, which is 64% below median its 10-year median of 9.52. BeBetter Med's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For BeBetter Med (SHSE:688759), the current Net Current Asset Value is ¥3.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BeBetter Med Inc is a biopharmaceutical company based in China, focusing on independent research and development of drugs. The company focuses on developing novel medicines for treating cancers, autoimmune diseases, and other severe conditions. Key products include the PI3K/HDAC dual inhibitor BEBT-908 and multiple drugs in clinical trial phases targeting cancers. It's a United States subsidiary BeBetter Pharma specializes in next-generation siRNA therapeutics using proprietary delivery platforms aimed at complex diseases like kidney disorders, metabolic and liver diseases, and neurodegenerative conditions. Its pipeline includes oral and injectable drug candidates, some in late-stage trials, and aims to address unmet medical needs through novel mechanisms.
4GF Score
Get the complete analysis for SHSE:688759
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688759 has been successfully added to your 
